10x Genomics Acquires Proteintech Genomics Division
TXG has more than doubled off its 52-week low of $9.21.
Summary
10x Genomics has acquired Proteintech Genomics, a division of Proteintech Group. This strategic acquisition follows the company's Q1 earnings report in early May, which highlighted reduced losses and the launch of its new Atera platform. The move indicates 10x Genomics is actively expanding its portfolio and capabilities within the genomics sector, potentially impacting future growth and market position.
At the time of this announcement, TXG was trading at $29.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $9.21 to $35.65. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.